loader from loading.io

Episode 431: Oncologic Emergencies 101: Urinary Obstruction

The ONS Podcast

Release Date: 09/04/2026

Episode 437: Precision Oncology: What We’ve Learned and What’s Ahead show art Episode 437: Precision Oncology: What We’ve Learned and What’s Ahead

The ONS Podcast

“Biomarker testing isn’t just about generating more information. It’s about answering very practical questions for our patients. Can we identify disease earlier? Can we understand whether treatment is working? Are we able to identify why a cancer has become resistant? Ultimately, I think that’s where precision oncology becomes very meaningful. It’s not about the molecular report sitting in the chart. It’s about taking that information and using it to make the best possible decision for our individual patients,” ONS member Erica Bello Rodriguez, MSN, AGNP, NP-C, AOCNP®, oncology...

info_outline
Episode 436: Oncologic Emergencies 101: Hypersensitivity Reactions show art Episode 436: Oncologic Emergencies 101: Hypersensitivity Reactions

The ONS Podcast

“The most important thing related to hypersensitivity reactions is that there is often a potential for rapid progression, and that’s what makes these reactions an oncologic emergency. The patients may have symptoms that are mild, and that quickly can progress to respiratory compromise, hypertension, cardiovascular issues, or anaphylaxis. Early recognition is so important, so we don’t want to wait for our patient to become hypotensive or significantly hypoxic before we identify that they’re having a serious reaction,” ONS member Christina Matousek, DNP, RN, OCN®, patient education...

info_outline
Episode 435: An Overview of Hodgkin Lymphoma for Oncology Nurses show art Episode 435: An Overview of Hodgkin Lymphoma for Oncology Nurses

The ONS Podcast

“The accumulation of these malignant and reactive cells, that’s what causes the lymph nodes to get big. That’s why they grow. And that’s why the classic presentation is persistent, painless, enlarged lymph nodes. So when we think of the pathophysiology of Hodgkin lymphoma, there are really two processes contributing to the presentation: One is the physical effects of enlarging lymph nodes or the involved organs. The second is the systemic inflammatory response generated by it and its surrounding immune environment,” ONS member Victoria Krogg, DNP, APRN-CNP, AOCNP®, nurse...

info_outline
Episode 434: Oncology–Psychiatric RN Collaboration to Support Psychosocial Health show art Episode 434: Oncology–Psychiatric RN Collaboration to Support Psychosocial Health

The ONS Podcast

“Nurses are the front line. Oncology nurses see their patients almost all day. If you’re noticing that anxiety is causing significant distress or anxiety is disrupting a patient’s ability to concentrate during medical conversations or decision-making—anytime you’re seeing significant distress or disruption to functioning, that’s a pretty good indicator that referral to a psychiatric nurse and psychiatric care could be very helpful for that patient,” Amber Altidor, DNP, APRN-FPA, PMHNP-BC, assistant professor at Rush University College of Nursing and psychiatric nurse practitioner...

info_outline
Episode 433: Cancer Treatments for Noncancer Indications: Chemotherapy/Immunotherapy show art Episode 433: Cancer Treatments for Noncancer Indications: Chemotherapy/Immunotherapy

The ONS Podcast

“Unlike our cancer indications where we use these medications often to activate the immune system to target cancerous cells, in noncancer indications, the goal is really to either suppress an overactive immune or inflammatory cells or modulate the immune system. Immune modulation by use of chemotherapy and immunotherapy can help reduce abnormal inflammation, decrease autoantibody production, and also can alter T-cell and B-cell activity,” ONS member Kelsey Miller, MSN, RN, AGCNS-BC, OCN®, clinical nurse specialist in oncology and infusion therapy at Reading Hospital in West Reading, PA,...

info_outline
Episode 432: Long-Term Chronic Lymphocytic Leukemia Considerations for Oncology Nurses show art Episode 432: Long-Term Chronic Lymphocytic Leukemia Considerations for Oncology Nurses

The ONS Podcast

“It’s a chronic disease. It never goes away for some people, and so therefore it has these periods of remission where it’s really quiet and well controlled. Then there can be periods of flares where you’re actively engaged in treatment or it’s impacting other pieces. There’s this feeling patients have of, ‘When am I going to have that flare?’ You know, this anticipatory anxiety of, ‘When are things going to be done differently?’ or ‘When do I need to change?’” ONS member Caitlin Murphy, DNP, APRN, FNP-BC, AOCNP®, chief nurse practitioner at Dana-Farber Cancer...

info_outline
Episode 431: Oncologic Emergencies 101: Urinary Obstruction show art Episode 431: Oncologic Emergencies 101: Urinary Obstruction

The ONS Podcast

“Think about all the important things our kidneys do for the body. Those things are compromised. If we have excess buildup of toxins and waste in the body, you’re having problems with fluid reabsorption. Then you have also problems with electrolytes not being balanced. Then in turn, you have ongoing shutdown of systems. So the cardiopulmonary system gets compromise. Your circulatory system then gets compromised. And then all the things in the body that depend upon ongoing circulatory flow are then causing major resets in the system that need to be addressed,” ONS member Brenda S....

info_outline
Episode 430: Leadership Unlocked: Is It Your Time to Serve? show art Episode 430: Leadership Unlocked: Is It Your Time to Serve?

The ONS Podcast

“If you are considering board service, I would say take the leap. Start with your local chapter. It will give you some valuable skills that will help prepare you when you are applying for your national level. And I always say, if you want to do it, just do it because what’s the worst that can happen? They can say no, but that doesn’t mean that you will never serve on a board. I always tell people delayed is not denied,” Cassandra Green, DNP, RN, OCN®, ONS member and past president of the Oncology Nursing Certification Corporation (ONCC) Board of Directors, told Evelyn Wempe, DNP,...

info_outline
Episode 429: Radiation Site-Specific Side Effects: CNS Cancers show art Episode 429: Radiation Site-Specific Side Effects: CNS Cancers

The ONS Podcast

“They’re really worried that radiation is going to be painful. So they come in for that first day of treatment very anxious. With our patients with brain cancer, we’re using the masks on the table, and those masks are very tight and hold their heads very, very still. So they’ll be very worried about being claustrophobic. We may start out the first day or two with a little bit of [lorazepam]. And they’ll come to me and they’ll say, ‘This really hasn’t been as bad as I thought it was going to be,’” ONS member Catherine McCluskey, BSN, RN, OCN®, ROCN™, radiation oncology...

info_outline
Episode 428: Chronic Lymphocytic Leukemia Treatment Considerations for Oncology Nurses show art Episode 428: Chronic Lymphocytic Leukemia Treatment Considerations for Oncology Nurses

The ONS Podcast

“Measurable residual disease is where I think the terminology fits best in that, it is intended to measure the amount of cancer cells that are present in the blood or bone marrow at the time the sample was collected. We can identify one cancer cell in a million. Where that can be really valuable is when we start to think about the duration of treatments and the response to some of our treatments,” ONS member Caitlin Murphy, DNP, APRN, FNP-BC, AOCNP®, chief nurse practitioner at Dana-Farber Cancer Institute in Boston, MA, told Lenise Taylor, MN, RN, AOCNS®, TCTCN™, oncology clinical...

info_outline
 
More Episodes

“Think about all the important things our kidneys do for the body. Those things are compromised. If we have excess buildup of toxins and waste in the body, you’re having problems with fluid reabsorption. Then you have also problems with electrolytes not being balanced. Then in turn, you have ongoing shutdown of systems. So the cardiopulmonary system gets compromise. Your circulatory system then gets compromised. And then all the things in the body that depend upon ongoing circulatory flow are then causing major resets in the system that need to be addressed,” ONS member Brenda S. Nettles, DNP, MS, ACNP-BC, AOCNP, CNE, assistant professor at the Johns Hopkins School of Nursing and nurse practitioner at Johns Hopkins Hospital in Baltimore, MD, told Madeline Johnston, MSN, RN, OCN®, oncology clinical specialist at ONS, during a conversation about urinary obstructions.

Music Credit: “Fireflies and Stardust” by Kevin MacLeod

Licensed under Creative Commons by Attribution 3.0 

Earn 0.25 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by September 4, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Learning outcome: Learners will report an increase in knowledge relating to urinary obstruction as an oncologic emergency.

Episode Notes 

To discuss the information in this episode with other oncology nurses, visit the ONS Communities.

To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library.

To provide feedback or otherwise reach ONS about the podcast, email [email protected].

Highlights From This Episode

“As far as diagnoses go, I think that the ones that we see most common are impacted by the actual genitourinary system itself being impacted, so your patients with prostate cancer and patients with bladder cancer are definitely the ones that we see most often. But you’ll see that it’s also in individuals that have a diagnosis of either mucinous neoplasms or invasive peritoneal disease that invades all the cavities of the body—and also your sarcomas, because they also will actually the involve different parts of the renal system as part of their spread pattern.” TS 3:55

“The first thing you want to do is try to eliminate the causative factor. So what’s causing the obstruction? If there’s something that’s limiting flow because of the compression from the outside of the ureter or compressing around the kidney itself that they can’t drain adequately, then you can look at ways to manage that by inserting a nephrostomy tube into the kidney. You can also put in ureteral stents to help alleviate the pressure from drainage from the kidney to the ureter and into the bladder.” TS 7:20

“It’s very common when people have a partial obstruction to have still some degree of urinary output. But the key thing is looking at, over time, how that may change. So if they do develop some progressive symptoms of the flank pain, and then also renal function begins to get a little bit lower and lower over time. Hematuria or signs of infection—those are again that next-level discussion that needs to be had about what gets evaluated next to confirm a possible obstruction.” TS 10:00

“The biggest misconception, I believe, would be that you have time to figure it out. And the individual that already has immunocompromised states and also possible decline in baseline renal function have very low thresholds for us to really wait on these things too long. It’s always better to err on the side of caution and do at least the due diligence of minimal evaluation by looking at the individual’s vital signs and looking at their ability to still have urine output. Then if that’s now compromised, work further into the process in a more timely manner.” TS 13:47

“It’s always good to have a refresher about how to manage different types of urinary diversion systems, so check with your facility in regards to what they carry for nephrostomy tube devices and the maintenance plans they have for those as far as frequency of flushing. So you can be a problem solver for your individual that has these diversion devices place for urinary obstructions.” TS 16:19